*PUBLICATIONS*

Yiasemides E, Walton J, Marr P, Villanueva E, **Murrell DF**: A comparative study of transmission electron microscopy vs immunofluorescence mapping for the diagnosis of epidermolysis bullosa. Am J Dermatopath Oct;28(5):387-94 , 2006.

Figueira EC, Crotty A, Challinor CJ, Coroneo MT, **Murrell DF**: Granulation tissue in the eyelid margin and conjunctiva in junctional epidermolysis bullosa with features of LOC syndrome. Clin Experiment Ophthalmol Mar;35(2):163-6, 2007.

Rubin AI, Moran K, Fine J-D, Wargon O, **Murrell DF**: Urethral Meatal Stenosis In Junctional Epidermolysis Bullosa: A Rare Complication Effectively Treated With A Novel, And Simple Modality. Int J Dermatol (on line early 19 July 2006) 46:1076-1077, 2007. (Oct) doi: 10.1111/j.1365-4632.2006.03065.x

**Murrell DF**, Pasmooij AM, Pas HH, Marr P, Klingberg S, Pfendner E, Uitto J, Sadowski S, Collins F, Widmer R, Jonkman MF. Retrospective diagnosis of fatal BP180-deficient non-Herlitz junctional epidermolysis bullosa suggested by immunofluorescence (IF) antigen-mapping of parental carriers bearing enamel defects.J Invest Dermatol. 2007 Jul;127(7):1772-5.

Dang NN, Klingberg S, Marr P, **Murrell DF**: Review of Collagen VII sequence variants found in Australasian patients with dystrophic epidermolysis bullosa reveals 9 novel COL7A1 variants. J Dermatol Sci 46(3) June:169-178, 2007. Epub 2007 Apr 10.

Yiasemides E, Trisnowati N,Su J, Dang NN, Klingberg S, Marr P, Chow CW, Orchard D, Varigos G, **Murrell DF**: Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14. Clin Exp Dermatol. Nov 33(6):689-97.2008 doi 10.1111/j.1365-2230.2008.02858.x

Martin LK, Agero A, Werth V, Villanueva E, Segall J, **Murrell DF**: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus (protocol). The Cochrane Database of Systematic Reviews, Issue 3, 2006.

Dang NN, Klingberg S, Rubin AI, Edwards M, Borelli S, Relic J, Marr P, Tran K Turner A, **Murrell DF**: Differential expression of pyloric atresia in junctional epidermolysis bullosa with novel ITGB4 mutations. Acta Derm Venereol 88(5): 438-448, 2008 (accepted with revisions Mar 08). DOI 10.2340/00015555-0484. Featured with an accompanying editorial by Leena Bruckner-Tuderman.

Shipman AR, Agero AL, Cook I, Scolyer RA, Craig P, Pas HH, Wojnarowska F, **Murrell DF**: Epidermolysis Bullosa Acquisita Requiring Multiple Oesophageal Dilatations. Clin Exp Dermatol Nov;33(6):787-9, 2008. Epub 2008 Jul 4. Doi 10.1111/j.1365-2230.2008.02875.x

Dang NN, **Murrell DF**: Mutation analysis and characterization of COL7A1 mutations with dystrophic epidermolysis bullosa. Exp Dermatol, 17; 553-568., 2008 (Impact factor 2.449; 7/39 derm journals). 57. Murrell DF, Amagai M, Barnadas M, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Goldsmith L, Hall R, Harman KE, Hashimoto T, Hertl M,Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman N,Martin LK, Mimouni D, Pandya A, Payne A, Rubenstein D, Shimizu H, Sinha A, Sirois D, Dick S, Werth V: Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. J Am Acad Dermatol 58(June): 1043-6, doi 10.1016/j.jaad.2008.01.012)

Frew JW, Martin LK, Nijsten T, **Murrell DF**: Development of a quality of life index for epidermolysis bullosa (EB) through the development of the QOLEB questionnaire, an EB-specific quality of life instrument.. Br J Dermatol Dec;161(6):1323-30, 2009. Epub 2009 Jun 11. DOI 10.1111/j.1365. 2133.2009.09347.x

Shipman AR, Ali L, **Murrell DF,** Wojnarowska F. Mucous Membrane Pemphigoid: Laminin 5 Antibodies a Risk Factor for Laryngeal Involvement?. J Eur Acad Dermatol Venereol 2009 Feb;23(2):169-70. Epub 2008 Aug 27. DOI: 10.1111/j.1468-3083.2008.02921.x.

Fine JD, Eady RA, Bauer EA, Bauer J, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, , Jonkman MF, Leigh I, McGrath JA, Mellerio JE, **Murrell DF**, Shimizu H, Uitto J, Vahlquist A, Woodley D, Zambruno G, Revised Consensus for Definitions of Epidermolysis Bullosa. J Am Acad Dermatol 58(June): 931-950, 2008 (in press Dec 2007; advance on line March 2008. doi:10.1016/j.jaad.2008.02.004) Featured on front cover of journal.

Martin LK, Agero ALC, Werth V, Villanueva E, Segall J, **Murrell DF**: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus. The Cochrane Database of Systematic Reviews, Review 2009 Jan 21;(1):CD006263

Rosenbach M, **Murrell DF,** Bystryn J-C, Delay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittoria C, Werth BB, Williams EA, Taylor L, Troxel A, Werth VP: Comparison of reliability and validity between two outcome instruments for pemphigus. J Invest Dermatol ; 109: 2404-2410, 2009 doi:10.1038/jid.2009.72. Featured on front cover of journal as ‘outcome instruments for pemphigus’ with two other papers; accompanying commentary on ‘How to validate instruments for pemphigus’ by S. Bastuji-Garin and E Sbidian, JID p2328-9.

Nading MA, Lahmar JJ, Frew JW, Ghionis N, Hanly M, Kemble-Welch A, **Murrell DF**: A ski and adventure camp for young patients with severe forms of epidermolysis bullosa. J Am Acad Dermatol 61(3) 508-511, 2009. DOI 10.1111/j.1365-2133.2009.09347.x69. Winner of Sarkany Travel Award to Dr Nading, EADV Paris 2008.

Lara-Corrales I, Mellerio J, Lucky AW, Azizkhan RG, **Murrell DF**, Agero ALC, Kantor P, Pope E. Dilated Cardiomyopathy in Epidermolysis Bullosa, a retrospective, multicenter study. Pediatr Dermatol 27:238-243, 2010.

Kho YC, Agero AL, Rhodes LM, Robertson S, Su J, Varigos G, Robertson I, Hogan P, Orchard D, **Murrell DF**. Epidemiology of EB in the Antipodes: the Australasian EB Registry with a focus on Herlitz Junctional EB. Arch Dermatol 146(6): 635-60, 2010. (featured on the front cover of the journal). Winner of UNSW Dean’s List Award to student Yong Kho 2010.

Venugopal SS, Intong LRA, Cohn HI, Mather-Hillon J, **Murrell DF**: Responsiveness of non-Herlitz junctional epidermolysis bullosa to topical gentian violet. Int J Dermatol 2010 Nov;49(11):1282-5. doi: 10.1111/j.1365-4632.2010.04557.x.

Frew JW &amp; **Murrell DF**: Quality of Life Measurements in Epidermolysis Bullosa: Tools for Clinical Research &amp; Patient Care. Dermatol Clin N Am, 28(1):185-190, 2010,

Cohn HI &amp; **Murrell DF**: Laryngo-onycho-cutaneous syndrome. Dermatol Clin N Am, 2010, Part I: Epidermolysis Bullosa, 28 (1): 89-93, 2010.

Tosti A, Duque-Estrada B, **Murrell DF**: Alopecia in Epidermolysis Bullosa. Dermatol Clin N Am, 28 (1): 165-170, 2010

Tosti A, Cadore de Farias D, **Murrell DF**: Nail involvement in Epidermolysis Bullosa. Dermatol Clin N Am, 28 (1): 153-158, 2010

Figuiera EC, **Murrell DF**, Coroneo MT: Epidermolysis Bullosa and the Eye. Dermatol Clin N Am, 28 (1): 143-152, 2010

Intong LRA, &amp; **Murrell DF**: How to Take Skin Biopsies for Epidermolysis Bullosa. Dermatol Clin N Am, 28 (2): 197-200, 2010.

Venugopal SS & amp; **Murrell DF**: Management of Squamous Cell Carcinoma in Epidermolysis Bullosa. Dermatol Clin N Am, 28 (2): 283-288, 2010.

Yan WF, **Murrell DF**: Cell therapy for dystrophic epidermolysis bullosa. Dermatol Clin N Am, 28 (2): 367-370, 2010.

**Murrell DF**: Epidermolysis Bullosa in Australia and New Zealand. Dermatol Clin N Am, 28 2): 433-438, 2010.

Sebaratnam DF, Martin LK, Rubin AI, Tran K, Pas HH, Marr PJ, Edmonds J, **Murrell DF**: Reversible relapse of pemphigus foliaceus triggered by topical imiquimod suggests Toll-like receptor 7 inhibitors may be useful treatments for pemphigus. Clin Exp Dermatol. Jan;36(1):91-3. doi: 10.1111/j.1365-2230.2010.03918.x. Epub 2010 Sep 1. Jan 2011 (image from article featured on front cover of journal).

Martin LK, Werth VP, Villanueva E, **Murrell DF**: A systematic review of randomized controlled trials for Pemphigus Vulgaris and Pemphigus Foliaceus. J Am Acad Dermatol May;64(5):903-8, 10.1016, 2011.

Choi SD, Intong LRA, Kho YC, Rhodes LM, Chapman MG, **Murrell DF**: Outcomes of 11 pregnancies in 3 patients with recessive forms of epidermolysis bullosa. Br J Dermatol Sep;165(3):700-1, 2011. doi: 10.1111/j.1365-2133.2011.10441.x.

Purdie K, Pourreyron C, Fassihi H, Cepeda R, Volz A, Weissenborn S, Pfister H, Proby C, Bruckner-Tuderman L, **Murrell DF**, Salas-Alanis JC, McGrath JA, Leigh IM, Harwood C, South AP: Squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa are not associated with high risk mucosal human papillomaviruses and do not exhibit increased infection of beta papillomaviruses. J Invest Dermatol :130(12): 2853-5, 2010. DOI 10.1038/jid2010.243).

Frew JW, Lim S-W, Klausseger A, Chow CW, Tran K, Su J, Orchard D, Varigos G, Sawamura D, Nishie W, Shimizu H, **Murrell DF**: Autosomal Dominant Bullous Dermolysis of the Newborn Associated with a Heterozygous Mis-sense Mutation p.G1673R in Type VII Collagen. Australas J Dermatol 2010 Published Online 23/8/10 Nov;52(4):e1-4. DOI: 10.1111/j.1440-0960.2010.00684.

Daniel BS and **Murrell DF**. The actual management of pemphigus. G Ital Dermatol Venereol. 2010 Oct;145(5):689-702.

Kirtschig G, Middleton P, Bennett C, **Murrell DF** Wojnarowska F, Khumalo N, Interventions for bullous pemphigoid. The Cochrane Database of Systematic Reviews Issue 10, 2010 Oct 6;10:CD002292. (88 citations)

Yiu EM, Klausegger AK, Waddell LB, Grasern N, Lloyd L, Tran K, North KN, Bauer JW, McKelvie P, Chow CW, Ryan MM, **Murrell DF**. Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiency. Muscle Nerve Jul;44(1):135-41, 2011. doi: 10.1002/mus.22076.

Martin LK, **Murrell DF**: Pemphigus: Directions for the future. J Am Acad Dermatol. May; 64(5):909-10, 2011.

Venugopal S &amp; **Murrell DF**: Diagnosis and Clinical features of pemphigus vulgaris. Dermatol Clin Jul;29(3):373-80, vii, 2011.

Sebaratnam DF, Frew JW, Davatchi F &amp; **Murrell DF**: Objective scoring systems for disease activity in autoimmune blistering diseases. Dermatol Clin Jul;29(3):515-20, xi, 2011.

Chee SN &amp; **Murrell DF**: Pemphigus and Quality of Life. Dermatol Clin Jul;29(3):521-5, xi-ii.: 2011.

Intong LRA &amp; **Murrell DF**: Pemphigoid gestationes: Pathogenesis and Clinical Features. Dermatol Clin Jul;29(3):447-52, ix. 2011

Tosti A, Andre M **Murrell DF**: Nail involvement in autoimmune blistering diseases. Dermatol Clin Jul;29(3):511-3, xi. 2011.

Miteva M, **Murrell DF**, Tosti A: Hair loss in autoimmune cutaneous bullous disorders. Dermatol Clin Jul;29(3):503-9, xi, 2011.

**Murrell DF**, Trisnowati N, Miyakis S and Paller AS: The yin and the yang of keratin amino acid substitutions and epidermolysis bullosa simplex. J Invest Dermatol Sep 131 (() 1878-90, 2011 (invited commentary containing novel findings). doi: 10.1038/jid.2011.206. (1/40; IF 6)

Frew JW, **Murrell DF**. Corticosteroid Use in Autoimmune Blistering Diseases. Dermatol Clin. 2011 Oct;29(4):535-44

Daniel BS, **Murrell DF**, Joly P. Rituximab and its use in autoimmune bullous disorders. Dermatol Clin. 2011 Oct;29(4):571-5

Daniel BS, Borradori L, Hall RP, **Murrell DF**: Evidence-based management of bullous pemphigoid. Dermatol Clin 29 (4): 2011. doi:10.1016/ j.det.2011.06.003.

Chee SN, **Murrell DF**: The use of intravenous immunoglobulin in autoimmune blistering diseases. Dermatol Clin 29 (4): 2011 doi:10.1016/j.det.2011.06.010.

Frew JW, **Murrell DF**: Paraneoplastic pemphigus (Paraneoplastic autoimmune multiorgan syndrome) Pathogenesis and clinical features. Dermatol Clin Jul;29(3):419- 25, viii. 2011

Gupta VK, Kelbel TE, Nguyen D, Melonakos KC, **Murrell DF**, Xie Y, Mullard A, Reed PL, Seiffert-Sinha K, Sinha AA. A globally available internet-based patient survey of pemphigus vulgaris: epidemiology and disease characteristics. Dermatol Clin. Jul;29(3):393-404, vii-iii, 2011.

Lehman JS, **Murrell DF**, Camilleri MJ, Kalaaji AN. Infection and Infection Prevention in Patients Treated with Immunosuppressive Medications for Autoimmune Bullous Disorders. Dermatol Clin. 2011 Oct;29(4):591-8.

Frew JW, Martin LK, **Murrell DF**. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011 Oct;29(4):599-606.

Daniel BS, Dermawan A, **Murrell DF**. The autoimmune blistering diseases in Australia: status and services. Dermatol Clin. 2011 Oct;29(4):687-90. 118. Murrell DF, Werth VP, Segall J, Zrnchik W, Stuart M, Sirois D.The international Pemphigus and Pemphigoid Foundation. Dermatol Clin. 2011 Oct;29(4):655-7.

Sebaratnam DF, **Murrell DF**. Bullous systemic lupus erythematosus. Dermatol Clin. 2011 Oct;29(4):649-53.

Intong LR, **Murrell DF**. Management of epidermolysis bullosa acquisita. Dermatol Clin. 2011 Oct;29(4):643-7.

Intong LR, **Murrell DF.** Pemphigoid gestationis: current management. Dermatol Clin. 2011 Oct;29(4):621-8.

Kopecki Z, Arkell RM, Strudwick XL, Hirose M, Ludwig RJ, Kern JS, Bruckner- Tuderman L, Zillikens D, **Murrell DF**, Cowin AJ. Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of Epidermolysis Bullosa Acquisita. J Pathol. Nov;225(3):401-13, 2011. doi: 10.1002/path.2973.

**Murrell DF,** Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha A, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman MF, Pandya AG, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM Jr, Schmidt E, Shimizu H, Zone J, Swerlick R, Culton D, Lipozencic J, Bince B, Mimouni D, Grando S, Bystryn JC, Werth VP. Definitions and Outcome Measures for Bullous Pemphigoid: Recommendations by an International Panel of Experts. J Am Acad Dermatol. Mar;66(3):479-85, 2012. DOI: 10.1016/j.jaad.2011.06.032

Sebaratnam DF, Frew JW, Davatchi F, **Murrell DF**. Quality of life measurement in blistering diseases. Dermatol Clin. 2012 Apr;30(2):301-7. Epub 2011 Dec 20.

Intong LRA, **Murrell DF**: Inherited EB: New diagnostic criteria and classification. Clin Dermatol. 2012 Jan-Feb;30(1):70-7. doi: 10.1016.

Sebaratnam DF, McMillan JR, Werth VP, **Murrell DF**. Quality of life in patients with bullous dermatoses. Clin Dermatol. 2012 Jan-Feb;30(1):103-7. doi: 10.1016/j.clindermatol.2011.03.016.

Daniel BS, Hertl M, Werth VP, Eming R, **Murrell DF**. Severity score indexes for blistering diseases. Clin Dermatol. 2012 Jan-Feb;30(1):108-13. doi: 10.1016/j.clindermatol.2011.03.017.

Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, Israeli S, Sagiv N, Martinez de Morentin H, Katz O, Baum S, Barzilai A, Trau H, **Murrell DF**, Bergman R, Hertl M, Rosenberg S, Nöthen MM, Skorecki K, Schmidt E, Zillikens D, Darvasi A, Geiger D, Rosset S, Ibrahim SM, Sprecher E. Population-Specific Association between a Polymorphic Variant in ST18, Encoding a Pro-Apoptotic Molecule, and Pemphigus Vulgaris. J Invest Dermatol. 2012 Mar 22. doi: 10.1038/jid.2012.46

Venugopal SS, **Murrell DF**. Diagnosis and clinical features of pemphigus vulgaris. Immunol Allergy Clin North Am. 2012 May;32(2):233-43.

Frew JW, **Murrell DF**. Corticosteroid use in AIBD. Immunol Allergy Clin North Am. 2012 May;32(2):283-94.

Chee SN, **Murrell DF**. Use of Intravenous immunoglobulin in autoimmune blistering diseases. Immunol Allergy Clin North Am. 2012 May;32(2):323-30. 133. Daniel BS, Murrell DF, Joly P. Rituximab and its use in autoimmune blistering disorders. Immunol Allergy Clin North Am. 2012 May;32(2):331-7.

**Murrell DF**: Autoimmune diseases of the skin. Immunol Allergy Clin North Am. 2012 May;32(2):xiii-xiv.

Ng YZ, Pourreyron C, Salas-Alanis JC, Dayal JH, Cepeda-Valdes R, Yan W, Wright S, Chen M, Fine JD, Hogg FJ, McGrath JA, **Murrell DF,** Leigh IM, Lane EB, South AP. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.Cancer Res. Jul 15;72(14):3522-34, 2012.

Wriston CC, Rubin AI, Martin LK, Kossard S, **Murrell DF.** Plaque like cutaneous mucinosis. Am J Dermatopathol. 2012 Jun;34(4):e50-4.

Daniel BS, **Murrell DF**. Intravenous immunoglobulin: recent advances in the treatment of autoimmune bullous diseases. G Ital Dermatol Venereol. 2012 Jun;147(3):259-67.

Hwang S, Kim MH, Kemble Welch A, Hanley MC, **Murrell DF**. Volunteering at an adventure camp for epidermolysis bullosa. Med J Aust. 2012 2012 Jul 5;197(1):54.

Kopecki Z, Ruzehaji N, Turner C, Iwata H, Ludwig RJ, Zillikens D, **Murrell DF**, Cowin AJ. Topically applied Flightless I neutralising antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita. J Invest Dermatol 6 th Dec 2012 doi:10.1038/jid.2012.457.

Kim J, Teye K, Koga H, Yeoh SC, Wakefield D, Hashimoto T, **Murrell DF**. Successful single cycle rituximab treatment in a pemphigus vulgaris patient with squamous cell carcinoma of the tongue and IgG antibodies to desmocollins. J Am Acad Dermatol 2013 Jul;69(1):e26-7. doi: 10.1016/j.jaad.2012.12.967

Kim MH, Li M, Intong LRA,Tran K, Melbourne W, Marucci D, Bucci J, de Souza P, Mallesara G, **Murrell DF**: Use of cetuximab as an adjuvant agent to radiotherapy and surgery in Recessive Dystrophic Epidermolysis Bullosa with Squamous Cell Carcinoma. Br J Dermatol 2013 Feb 12. doi: 10.1111/bjd.12272.

Ramirez M, **Murrell DF,** Fine JD. Management of Epidermolysis Bullosa Exp Opin Orph Drugs. Apr 2013, Vol. 1, No. 4, Pages 279- 293.DOI:10.1517/1678707.2013.774272

Daniel BS, **Murrell DF**, Borradori L. Management of Bullous Pemphigoid. Exp Opin Orph Drugs. May 2013, Vol. 1, No. 5, Pages 405-412

Kim J, Loh CH, **Murrell DF**. Epidermolysis bullosa pruriginosa triggered by scabies infestation J Dermatol. 2013 May 10. doi: 10.1111/1346-8138.12167.

**Murrell DF**: The pitfalls of skin biopsies for the diagnosis of epidermolysis bullosa Pediatr Dermatol. 2013 Mar-Apr;30(2):273-5. doi: 10.1111/pde.12095

Sebaratnam DF, Hanna AM, Chee SN, Frew JW, Venugopal SS, Daniel BS, Martin LK, Rhodes LM, Tan JC, Wang CQ, Welsh B, Nijsten T, **Murrell DF**. Development of a Quality-of-Life Instrument for Autoimmune Bullous Disease: The Autoimmune Bullous Disease Quality of Life Questionnaire.JAMA Dermatol. JAMA Dermatol. 2013 Oct;149(10):1186-91. doi: 10.1001/jamadermatol.2013.4972.

Frew JW, Cepeda-Valdes R, Fortuna G, **Murrell DF**, Salas-Alanis J: Measuring Quality of Life in Epidermolysis Bullosa in Mexico: Cross Cultural Validation of the Hispanic Version of the Quality of Life in Epidermolysis Bullosa Questionnaire. J Am Acad Dermatol 2013 Oct;69(4):652-3. doi: 10.1016/j.jaad.2013.04.053

Venugopal SS, Yan W, Frew JW, Cohn HI,Rhodes LM, Tran K, Melbourne W, Nelson JA, Sturm M, Fogarty J, Marinkovich MP, Igawa S, Ishida-Yamamoto A, **Murrell DF**. A phase II randomized vehicle controlled trial of intradermal allogeneic fibroblast therapy for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol Sep 24. doi:pii: S0190-9622(13)00864-5. 10.1016/j.jaad.2013.08.014 (accepted Aug 13 th , 2013).

Tjokrowidjaja A, Daniel BS, Frew JW, Sebaratnam DF, Hanna AM, Chee SN, Dermawan A, Wang CQ, Lim C, Venugopal SS, Rhodes LM, Welsh B, Nijsten T, **Murrell DF.** The development and validation of the TABQOL, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol Nov;169(5):1000-6 DOI: 10.1111/bjd.12623 with accompanying editorial by Andrew Finlay mentioning its significance.

Loh CH, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, Intong LRA, Law MG and **Murrell DF**. Development, Reliability and Validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol 2014 Jan;70(1):89-97.e13. doi: 10.1016/j.jaad.2013.09.041.

Dayal J, Cole C, Pourreyron C, Watt S, Lim Y, Salas-Alanis J, **Murrell DF,** McGrath J, Steiger B, Jahoda C, Leigh I, and South AP. Type VII collagen regulates tumour expression of organic anion transporting polypeptide OATP1B3, promotes front to rear polarity and increases structural organisation in 3D spheroid cultures of recessive dystrophic epidermolysis bullosa tumour keratinocytes. J Cell Sci 2014 Feb 15;127(Pt 4):740-51. doi: 10.1242/jcs.128454

**Murrell DF**, Amagai M, Werth VP: Why bother with scoring systems for blistering diseases in practice and which one should you use? Invited editorial. JAMA Dermatol 2014 Jan 15. doi: 10.1001/jamadermatol.2013.8179.

Yuen QY, Frew JW, Veerman K, Van den Heuvel ER, **Murrell DF**, Jonkman MF: Health related quality of life in epidermolysis bullosa: validation of the Dutch QOLEB Questionnaire and assessment in the Dutch population. Acta Derm Venereol 2013 Dec 12. doi: 10.2340/00015555-17582013.

Kopecki Z, Yang GN, Arkell RM, Jackson JE, Melville E, Iwata H, Ludwig RJ, Zillikens D, **Murrell DF**, Cowin AJ: Flightless I overexpression impairs skin barrier development, function and recovery post skin blistering. J Pathol Dec 28, 2013 e pub. DOI 10.1002/path 4323. Legaspi KNM, Murrell DF: Inherited Epidermolysis Bullosa (Review). Journal of the Egyptian Women’s Dermatologic Society. 11 (Jan): 1-13, 2014.

Fine JD, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, **Murrell DF**, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. diagnosis and classification. J Am Acad Dermatol online Mar 31, 2014. doi:10.1016/j.jaad.2014.01.903

Ludwig RJ, Borradori L, Diaz LA, Hashimoto T, Hertl M, Ibrahim SM, Jonkman MF, Kitajima Y, **Murrell DF,** Schmidt E, Shimizu H, Stanley JR, Woodley D, Zillikens D. From epidemiology and genetics to diagnostics, outcome measures and novel treatments in autoimmune bullous diseases. J Invest Dermatol 2014 Sep;134(9):2298-300. doi: 10.1038/jid.2014.171.

Hon KL, Li JJ, Cheng BL, Luk DC, **Murrell DF**, Choi PC, Leung AK. Age and etiology of childhood epidermolysis bullosa mortality. J Dermatolog Treat. 2014 May 15:1-5. PMID: 24724596

Zhao CY, **Murrell DF**.Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015 Feb;75(3):271-84. doi: 10.1007/s40265-015-0353-6. PMID: 25655250

Sebaratnam DF, **Murrell DF.** Dermatology training and practice in Australia. Int J Dermatol. 2014 Oct;53(10):1259-64. doi: 10.1111/ijd.12728.

Zhao CY, **Murrell DF**: Outcome Measures for Autoimmune Blistering Diseases. J. Dermatol. 2015 Jan;42(1):31-6. doi: 10.1111/1346-8138.12711.

**Murrell DF**, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, Amagai M, Bauer J, Beissert S, Borradori L, Culton D, Fairley JA, Fivenson D, Jonkman MF, Peter Marinkovich M, Woodley D, Zone J, Aoki V, Bernard P, Bruckner-Tuderman L, Cianchini G, Venning V, Diaz L, Eming R, Grando SA, Hall RP, Hashimoto T, Herrero- González JE, Hertl M, Joly P, Karpati S, Kim J, Chan Kim S, Korman NJ, Kowalewski C, Lee SE, Rubenstein DR, Sprecher E, Yancey K, Zambruno G, Zillikens D, Doan S, Daniel BS, Werth VP. Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts. J Am Acad

Dermatol. 2015 Jan;72(1):168-174. doi: 10.1016/j.jaad.2014.08.024. Epub 2014 Nov 4. 2014 Nov 4.

Hoste E, Arwert E, Lal R, South A, Salas-Alanis J**, Murrell DF**, Donati G, Watt F: Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun  2015 Jan 9;6:5932. doi: 10.1038/ncomms6932.

Zhao CY, **Murrell DF**: Autoimmune blistering diseases in females: a review. Intl J Women’s Dermatol 1:4-12, 2015. DOI: 10.1016/j.ijwd.2015.01.002

Intong LRA, Choi SD, Shipman AR, Kho YC, Hwang SJE, Rhodes LM, Walton JR, Chapman MG, **Murrell DF**. Retrospective evidence on outcomes and experiences of pregnancy and childbirth in Australia and New Zealand. Intl J Women’s Dermatol 1:26- 30, 2015. DOI: dx.doi.org/10.1016/j.ijwd.2014.12.005

Hwang SJE, Daniel BS, Fergie B, Davey J, O’Nions J, **Murrell DF**: Prevalence of anemia in patients with Epidermolysis Bullosa registered in Australia. Intl J Women’s Dermatol 1:37-40,2015 dx.doi.org/10.1016/j.ijwd.2014.12.001

Cestari T, Menegon D, Prati C, Najjar Z, Oliveira P, **Murrell DF**. Translation, cross- cultural adaptation and validation of the quality of life evaluation in epidermolysis bullosa (QOLEB) instrument into Brazilian Portugeuese. Int J Dermatol. 2015 Oct 16. doi: 10.1111/ijd.12819.

Tan JC, Tat LT, Francis KB, Mendoza CG, **Murrell DF**, Coroneo MT. Prospective study of ocular manifestations of pemphigus and bullous pemphigoid identifies a high prevalence of dry eye syndrome.Cornea. 2015 Apr;34(4):443-8. doi: 10.1097/ICO.0000000000000335.

Sebaratnam DF, Okawa J, Payne A, **Murrell DF**, Werth VP. Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. Qual Life Res. 2015 Mar 21. [Epub ahead of print] PMID:25795375 (IF 2.9)

Kim MH, **Murrell DF**: Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa. Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2. doi: 10.1684/ejd.2015.2552. PMID:26083672

Chaptini C, Casey G, Harris AG, D, **Murrell DF** Gordon L: Recessive dystrophic epidermolysis bullosa complicated by secondary hepatic amyloidosis. JAAD Case Rep 2015 Sep 24;1(6):337-9. doi: 10.1016/j.jdcr.2015.07.006. eCollection 2015 Nov.

Mellerio JE, Robertson SJ, Bernardis C, Diem A, Fine JD , George R, Goldberg D, Halmos GB , Harries M, Jonkman MF, Lucky A, Martinez AE, Maubec E, Morris S, **Murrell DF**, Palisson F,Pillay EI, A Robson, Salas-Alanis JC, McGrath JA: Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa – best clinical practice guidelines. Br J Dermatol Aug 24. doi: 10.1111/bjd.14104.2015

Oh DD, Zhao CY, **Murrell DF**: A review of case control studies on the risk factors for the development of autoimmune blistering diseases. JEADV 2016 Apr;30(4):595-603. doi: 10.1111/jdv.13386. Epub 2015 Oct 5.

Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, **Murrell DF**, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kähäri VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O&#39;Toole EA. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC. J Natl Cancer Inst. 2015 Oct 16;108(1). pii: djv293. doi: 10.1093/jnci/djv293. Print 2016 Jan. IF12.5

Kopecki Z, Yang G, Jackson J, Melville E, Calley M, **Murrell DF**, Darby I, O&#39;Toole E, Samuel M, Cowin A.Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression. Oncotarget. 2015 Oct 19. doi: 10.18632/oncotarget.5536. [Epub ahead of print] IF 6.34

Harris AG, Todes Taylor N, **Murrell DF**: An Analysis of the Rurality and Remoteness of patients with Epidermolysis Bullosa in Australia. Australas J Dermatol. 2016 Feb 5. doi: 10.1111/ajd.12431.

Chaptini C, Casey G, Harris AG, Watchow D, Gordon L, **Murrell DF**: Botulinum toxin A injection for chronic anal fissures and anal sphincter spasm improves quality of life in recessive dystrophic epidermolysis bullosa Int J Women’s Dermatol 1: (Dec) 167-169, 2015.

Turczynski S, Titeux M, Pironon N, Cohn HI, **Murrell DF**, Hovnanian A. Marked intrafamilial phenotypic heterogeneity in dystrophic epidermolysis bullosa caused by inheritance of a mild dominant glycine substitution and a novel deep intronic recessive COL7A1 mutation. Br J Dermatol. 2015 Nov 23. doi: 10.1111/bjd.14312.

Boulard C, Lehembre SD, Picard-Dahan C, Kern J, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost-Squarcioni C, Labeille B, Richard MA, Ingen-Housz- Oro S, Houivet D. Werth V, **Murrell DF**, Hertl M, Benichou J, Joly P. Calculation of cut-off values based on the ABSIS and PDAI pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol 2016 Jan 22. doi: 10.1111/bjd.14405.

Harris AG, Kim M, **Murrell DF**. Pigmented Hair-Thickening Fibers: A Camouflage Technique for Alopecia in Patients with Epidermolysis Bullosa. Skin Appendage Disord. 2016 Feb;1(3):153-5. doi: 10.1159/000441661. Epub 2015 Dec 19.

Zhao CY, Chiang YZ, **Murrell DF**. Neonatal Autoimmune blistering diseases: a systematic review. Pediatr Dermatol. 2016 Apr 18. doi: 10.1111/pde.12859. 213. Zhao CY, Murrell DF.Advances in understanding and managing bullous pemphigoid. F1000Res. 2015 Nov 20;4. pii: F1000 Faculty Rev-1313. doi: 10.12688/f1000research.6896.1. eCollection 2015. Review.

Kim MH, Yang A, **Murrell DF**. Epidermolysis bullosa – why does a multidisciplinary team approach matter? Turk J Dermatol 2016;10:70-7 • DOI: 10.4274/tdd.2986

Kim MH, Jain S, Harris AG, **Murrell DF**. Colchicine may assist in reducing granulation tissue in junctional epidermolysis bullosa. Int J Womens Dermatol 2016 May 19;2(2):56- 59. doi: 10.1016/j.ijwd.2016.04.001

Zhao CY, **Murrell DF**, Neonatal Blistering Diseases Curr Opin Pediatr. 2016 Aug;28(4):500-6. doi: 10.1097/MOP.0000000000000381.

Zhao CY, Chiang YZ, **Murrell DF**. Neonatal Autoimmune Blistering Disease: A Systematic Review. Pediatr Dermatol. 2016 Jul;33(4):367-74. doi: 10.1111/pde.12859. Epub 2016 Apr 18. Review.

Zhao CY, **Murrell DF**, Management of Autoimmune Blistering Diseases. Current Dermatology Reports, in press 2016 Feb

Wijayanti A, Zhao CY, Boettiger D, Chiang YZ, Ishii N, Hashimoto T, **Murrell DF**. The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use? Acta Derm Venereol. 2017 Jan 4;96(7):24-31. doi: 10.2340/00015555-2473.

Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone L, Lu N, **Murrell DF**, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2016 Jul 29. pii: annrheumdis-2016-210002. doi: 10.1136/annrheumdis- 2016-210002.

Jain SV, Harris AG, Su JC, Orchard D, Warren LJ, McManus H, **Murrell DF**. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2016 Aug 31. doi: 10.1111/jdv.13953.

Kim E, Harris A, Hyland V, **Murrell DF**. Digenic Inheritance in Epidermolysis Bullosa Simplex involving two novel mutations in KRT5 and KRT14. Br J Dermatol. 2016 Sep 9. doi: 10.1111/bjd.15053

Kim MH, Borradori L, **Murrell DF**. Autoimmune blistering diseases in the elderly: clinical presentations and management. Drugs Aging Oct;33(10):711-723 2016. DOI: 10.1007/s40266-016-0402-1

van Beek N, Dähnrich C, Johannsen N, Lemcke S, Goletz S, Hübner F, Di Zenzo G, Dmochowski M, Drenovska K, Geller S, Horn M, Kowalewski C, Medenica L, **Murrell DF,** Patsatsi A, Uzun S, Vassileva S, Zillikens D, Schlumberger W, Schmidt E. Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. J Am Acad Dermatol. 2016 Dec 28. May;76(5):889-894.e5 pii: S0190-9622(16)31043-X. doi: 10.1016/j.jaad.2016.11.002.

Hanna S, Kim M, **Murrell DF** Validation studies of outcome measures in pemphigus. Int J Women’s Dermatol. 2016 Dec 10;2(4):128-139. doi: 10.1016/j.ijwd.2016.10.003.

Chen G, Yang B, Zhang Z, Yang Q, Yan Z, **Murrell DF**, Zhang F: Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire: Reliability and validity. Indian J Derm VL 2017; doi: 10.4103/ijdvl.IJDVL\_538\_16 .

Chen G, Yang B, Zhang Z, Yang Q, Yan X, **Murrell DF,** Zhang F. Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire: Reliability and validity. Indian J Dermatol Venereol Leprol. 2017 May 8. doi: 10.4103/ijdvl.IJDVL\_538\_16

Kim EN, Harris AG, Bingham LJ, Yan W, Su JC, **Murrell DF**. A Review of 52 Pedigrees with Epidermolysis Bullosa Simplex Identifying Ten Novel Mutations in KRT5 and KRT14 in Australia. Acta Derm Venereol. 2017 May 31. doi: 10.2340/00015555-2715. 243. Castrillón MA, Murrell DF. Lupus profundus limited to a site of trauma: Case report and review of the literature. Int J Womens Dermatol. 2017 May 5;3(2):117-120. doi: 10.1016/j.ijwd.2017.03.002

Patsatsi A, Kokolios M, Kyriakou A, Lamprou F, Stylianidou D, Tsapas A, Goulis DG, **Murrell DF**, Sotiriadis D. Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. Acta Derm Venereol. 2017 Oct 2;97(9):1145-1147. doi: 10.2340/00015555-2737.

Amber KT, **Murrell DF,** Schmidt E, Joly P, Borradori L. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clin Rev Allergy Immunol. 2017 Aug 4. doi: 10.1007/s12016-017-8633-4.

Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, **Murrell DF**. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand. Acta Derm Venereol. 2017 Aug 30. doi: 10.2340/00015555-2781

Prost-Squarcioni C, Caux F, Schmidt E, Jonkman MF, Vassileva S, Kim SC, Iranzo P, Daneshpazhooh M, Terra J, Bauer J, Fairley J, Hall R, Hertl M, Lehman JS, Marinovic B, Patsatsi A, Zillikens D, Werth V, Woodley DT, **Murrell DF**: International Bullous Diseases Group - Consensus on Diagnostic Criteria for Epidermolysis Bullosa Acquisita. Br J Dermatol. 2017 Nov 22. doi: 10.1111/bjd.16138.

**Murrell DF**, Sprecher E. Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2017 Nov;177(5):1143-1144. doi: 10.1111/bjd.15947.

Yang A, Chin R, **Murrell DF**: Mucous membrane pemphigoid affecting the epiglottis and response to intravenous immunoglobulin therapy. Otolaryngol Case Rep 2017 doi.org/10.1016/j.xocr.2017.11.001

**Murrell DF**, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne AS, Daneshpazhooh M, Eming R, Jonkman MF, Mimouni D, Borradori L, Kim SC, Yamagami J, Lehman JS, Saleh MA, Culton DA, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman-Karakaş A, Bernard P, Korman NJ, Caux F, Drenovska K, Prost- Squarcioni C, Vassileva S, Feldman RJ, Cardones AR, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, Schmidt E, Aoki V, Grando SA, Shimizu H, Baum S, Cianchini G, Feliciani C, Iranzo P, Mascaró JM Jr., Kowalewski C, Hall R, Groves R, Harman KE, Marinkovich MP, Maverakis E, Werth VP. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol. 2018 Feb 10. pii: S0190- 9622(18)30207-X. doi: 10.1016/j.jaad.2018.02.021

Lee BWH, Tan JCK, Radjenovic M, Coroneo MT, **Murrell DF.** A review of scoring systems for ocular involvement in chronic cutaneous blistering diseases. Orphanet J Rare Dis. 2018 May 22;13(1):83. doi: 10.1186/s13023-018-0823-5. Review.

Wang EQ, Radjenovic M, Castrillón MA, Feng G, **Murrell DF**. The effect of autoimmune blistering diseases on work productivity. J Eur Acad Dermatol Venereol. 2018 May 6. doi: 10.1111/jdv.15062

Xuan RR, Yang A, **Murrell DF**. New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature. Int J Womens Dermatol. 2018 Feb 3;4(2):102-108. doi: 10.1016/j.ijwd.2017.10.001. eCollection 2018 Jun. Review.

Jain SV, **Murrell DF** Psychosocial impact of inherited and autoimmune blistering diseases. Int J Womens Dermatol. 2018 Jan 8;4(1):49-53. doi: 10.1016/j.ijwd.2017.11.004. eCollection 2018 Mar.

Chen JS, Yang A, **Murrell DF**. Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An Evidence Based Review. Exp Dermatol. 2018 Aug 17. doi: 10.1111/exd.13771.

Wang EQ, Castrillon Velasquez MA, **Murrell DF**: The effects of autoimmune blistering diseases on work productivity: A review. Int J Women’s Derm. 4: 131–138, 2018. doi.org/10.1016/j.ijwd.2017.11.001

Yang A, Uhlenhake E, **Murrell DF**: Pemphigoid gestationis and intravenous immunoglobulin therapy. Int J Women’s Derm 4: 166-169, 2018. doi.org/10.1016/j.ijwd.2018.03.007

Saleh MA, Zaraa I, Doss N, Saleh NA, **Murrell DF**: Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases’ patients using an Arabic version of the Autoimmune Bullous Disease Quality of Life and the Treatment of Autoimmune Bullous Disease Quality of Life questionnaires. Ann Brasiliens Dermatol 2019 Oct 17;94(4):399-404. doi: 10.1590/abd1806-4841.20197198. eCollection 2019. PMID: 31644610

Harris AG, Saikal SL, **Murrell DF**. Epidermolysis Bullosa Patients&#39; Perception of Surgical Wound and Scar Healing. Dermatol Surg. 2018 Sep 10. doi: 0.1097/DSS.0000000000001673.

Phan K, Goyal S, **Murrell DF**. Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies. Australas J Dermatol. 2018 Aug 23. doi: 10.1111/ajd.12899.

Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard- Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D&#39;Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, **Murrell DF**, Hertl M, Benichou J, Joly P; Large international validation study of the ABSIS and PDAI J Invest Dermatol. 2018 Oct 6. pii: S0022-202X(18)32360-1. doi: 10.1016/j.jid.2018.04.042.

**Murrell DF**, Caux F, Prost-Squarcioni C. Is the Oral Disease Severity Score going to be useful for dermatologists when assessing pemphigus? Br J Dermatol. 2018 Oct;179(4):816-817. doi: 10.1111/bjd.16911.

Lee J, Werth VP, Hall RP 3rd, Eming R, Fairley JA, Fajgenbaum DC, Harman KE, Jonkman MF, Korman NJ, Ludwig RJ, **Murrell DF**, Musette P, Naik HB, Sadik CD, Yamagami J, Yale ML, Payne AS. Perspectives from the 5 th International Pemphigus and Pemphigoid Foundation Scientific Conference. Front Med (Lausanne). 2018 Nov 8;5:306. doi: 10.3389/fmed.2018.00306.

Temel IC, Temel AB and **Murrell DF**. Ear, Nose and Throat Examination in Epidermolysis Bullosa and Procedural Approach; mini-review. Biomed J Sci&amp;Tech Res 9(5)-2018. BJSTR. MS.ID.001866. DOI: 10.26717/ BJSTR.2018.09.001866.

Temel IC, Temel AB and **Murrell DF**. Ear, Nose and Throat Approach in Autoimmune Blistering Diseases; mini-review. On J Otolaryngol &amp; Rhinol. 1(1): 2018. OJOR.MS.ID.000504.

Temel IC, Temel AB and **Murrell DF.** Ear, Nose, and Throat Involvement in Epidermolysis Bullosa. Mini-review. Journal of Otolaryngology and Neurotology- J Otolaryngol Neurotol Res, 1(1): 16-19, 2019.

Patsatsi A, Marinovic B, **Murrell D.** Autoimmune bullous diseases during pregnancy: solving common and uncommon issues. Int J Womens Dermatol. 2019 Jan 24;5(3):166- 170. doi: 10.1016/j.ijwd.2019.01.003. eCollection 2019 Jul. 1360750

Temel AB, Irican C, Uzun S, Feng G, **Murrell DF**, Karakaş AA. Quality of life in Turkish patients with autoimmune blistering diseases: reliability and validity of the ABQOL and TABQOL questionnaires in Turkish language and culture. Turk J Dermatol Turk J Dermatol 13(2), 27-34, 2019.

Yang A, Kim M, Craig P, **Murrell DF**. A Case Report of the Use of Rituximab and the Epidermolysis Bullosa Disease Activity Scoring Index (EBDASI) in a Patient with Epidermolysis Bullosa Acquisita with Extensive Esophageal Involvement. Acta Dermatovenerol Croat. 2018 Dec;26(4):325-328.

Chavez A, Licholai G, **Murrell DF**. Patients left behind. Rare dermatologic conditions miss the orphan drug development boom. J Am Acad Dermatol. 2019 Mar 14. pii: S0190- 9622(19)30427-X. doi: 10.1016/j.jaad.2019.03.013.

Yang A, Xuan R, **Murrell DF**: A new indirect immunofluorescence BIOCHIP method for the serological diagnosis of bullous pemphigoid: A review of literature. Aust J Dermatol doi: 10.1111/ajd.13034, 2019.

Daniel BS, **Murrell DF**. A review of Autoimmune Blistering Diseases: the Pemphigoid Diseases. J Eur Acad Dermatol Venereol. 2019 May 13. doi: 10.1111/jdv.15679. Review. PMID: 31087464

Xie D, Bilgic-Temel A, Abu Alrub N, **Murrell DF**. Pathogenesis and clinical features of alopecia in epidermolysis bullosa- a systematic review. Pediatr Dermatol. 2019 Jul;36(4):430-436. doi: 10.1111/pde.13866. Epub 2019 Jun 9. Review. PMID 31177584

Yeoh SC, Byth-Wilson K, **Murrell DF**, Schifter M, Lin MW, Fulcher DA. Pemphigus vulgaris disease activity: the role of antibodies to desmogleins and their isotype. J Oral Pathol Med. 2019 Jun 13. doi: 10.1111/jop.12913. PMID:31192484

Bilgic A, **Murrell DF**. Pemphigus vulgaris accompanied with amyotrophic lateral sclerosis: rare coincidence or pathogenic relationship? Eur J Dermatol. 2019 Jun 27. doi: 10.1684/ejd.2019.3577. PMID: 31251210

Yang A, Xuan R, Melbourne W, Tran K, **Murrell DF**. Validation of the BIOCHIP test in pemphigus vulgaris, foliaceus and bullous pemphigoid. J Eur Acad Dermatol Venereol. 2019 Jul 1. doi: 10.1111/jdv.15770. PMID: 31260565

Bilgic-Temel A, **Murrell DF**, Uzun S. Cutaneous leishmaniasis: a neglected disfiguring disease for women. Int J Womens Dermatol. 2019 Feb 10;5(3):158-165. doi: 10.1016/j.ijwd.2019.01.002. eCollection 2019 Jul.PMID:31360749

Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, **Murrell DF**, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A. Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. J Allergy Clin Immunol. 2019 Aug 23. pii: S0091-6749(19)31099-1. doi: 10.1016/j.jaci.2019.08.013.

Bilgic-Temel A, Das S, **Murrell DF**. Successful management of bullous pemphigoid with dimethylfumarate therapy. Int J Womens Dermatol. 2019 Feb 22;5(3):179-180. doi: 10.1016/j.ijwd.2019.02.001. eCollection 2019 Jul. PMID: 31360754

Yang A, Xuan RR, Melbourne W, Hashimoto T, Uzun S, Daneshpazhooh M, Yamagami J, Di Zenzo G, Mascaro JM Jr, Mahmoudi H, Patsatsi A, Drenovska K, Vassileva S, **Murrell DF**. Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. J Eur Acad Dermatol Venereol. 2019 Jul 20. doi: 10.1111/jdv.15817.

Bilgic A, **Murrell DF**. What is new in the clinical management of pemphigus. Expert Rev Clin Pharmacol. 2019 Sep 25. doi: 10.1080/17512433.2019.1670059.

Xie D, Bilgic-Temel A, Abu Alrub N, **Murrell DF**. Alopecia in Autoimmune Blistering : A Systematic Review of Pathogenesis and Clinical Features of Disease. Skin Appendage Disord. 2019 Aug;5(5):263-275. doi: 10.1159/000496836.

Bilgic A, **Murrell DF**: Toxicity of Glucocorticosteroids in Autoimmune Blistering Diseases. Mucosa 2(3) 30-38, 2019 DOI: 10.33204/mucosa.580103

Frew JW, **Murrell DF**: Improving clinical applications of quality of life scores in epidermolysis bullosa: defining clinically significant outcomes in the QOLEB questionnaire. Mucosa 2(3) 41-48, 2019 doi:10.33204/mucosa.581816

Xie D, Bilgic-Temel A, Abu Alrub N, Murrell DF. Pathogenesis and clinical features of alopecia in epidermolysis bullosa: A systematic review. Pediatr Dermatol. 2

Goodale EC, Varjonen KE, Outerbridge CA, Bizikova P, Borjesson D, **Murrell DF**, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, White SD. Efficacy of a Bruton’s Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. Vet Dermatol. 2020 Jan 3. doi: 10.1111/vde.12841

Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, Gault J, Gershkowitz J, Kopelan B, Hund M, **Murrell DF**. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020 Jan 3;15(1):1. doi: 10.1186/s13023-019-1279-y

van Beek N, Krüger S, Fuhrmann T, Lemcke S, Goletz S, Probst C, Komorowski L, Di Zenzo G, Dmochowski M, Drenovska K, Horn M, Jedlickova H, Kowalewski C, Medenica L, **Murrell D,** Patsatsi A, Geller S, Uzun S, Vassileva S, Zhu X, Fechner K, Zillikens D, Stöcker W, Schmidt E, Rentzsch K. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. J Am Acad Dermatol. 2020 Jan 28. pii: S0190- 9622(20)30133-X. doi: 10.1016/j.jaad.2020.01.049. PMID: 32004645

Has C, Bauer JW, Bodemer C, Bolling M, Bruckner-Tuderman L, Diem A, Fine JD, Heagerty A, Hovnanian A, Marinkovich P, Martinez AE, McGrath JA, Moss C, **Murrell DF**, Palisson F, Schwieger-Briel A, Sprecher E, Tamai K, Uitto J, Woodley DT, Zambruno G, Mellerio JE. Consensus re-classification of epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020 Feb 4. doi: 10.1111/bjd.18921. PMID:32017015

Kang M, Bilgic A, Radjenovic M, Murrell DF. Osteoporosis in bone health in autoimmune blistering disease: an evidence-based review. J Eur Acad Dermatol Venereol. 2020 Mar 2. doi: 10.1111/jdv.16334

Gibson M, Rogers CL, **Murrell DF**. Successful dapsone therapy in inherited epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2020 Feb 17. doi: 10.1111/jdv.16301.

Verheyden MJ, Bilgic A, **Murrell DF.** A review of drug induced bullous pemphigoid. Acta Derm Venereol 2020 Mar 16. doi: 10.2340/00015555-3457

Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, de Souza MP, **Murrell DF**, Marinkovich MP, Tang JY. Patient Reported Outcomes and Quality of Life in Recessive Dystrophic Epidermolysis Bullosa: A Global Cross-sectional Survey. J Am Acad Dermatol. 2020 Mar 18. pii: S0190-9622(20)30442-4. doi: 10.1016/j.jaad.2020.03.028

Shakshouk H, Daneshpazhooh M, **Murrell DF**, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol. 2020 Apr 10. pii: S0190- 9622(20)30544-2. doi: 10.1016/j.jaad.2020.04.005.

Ferries L, Gillibert A, Duvert-Lehembre S, Corbaux C, Alexandre M, Prost-Squarcioni C, Caux F, Delaporte E, Litrowski N, Boulard C, **Murrell DF**, Joly P, Hebert V. Sensitivity to change and Correlation between Autoimmune Bullous Disease Quality of Life questionnaires ABQOL and TABQOL, and objective severity scores. Br J Dermatol. 2020 May 6. doi: 10.1111/bjd.19173 PMID 32374931

Amy S. Paller, John Browning, Milos Nikolic, Christine Bodemer, **Dedee F. Murrell**, Willistine Lenon, Eva Krusinska, Allen Reha, Hjalmar Lagast, Jay A. Barth, on behalf of the ESSENCE Study Group. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin)

Amy S. Paller, John Browning, Milos Nikolic, Christine Bodemer, **Dedee F. Murrell**, Willistine Lenon, Eva Krusinska, Allen Reha, Hjalmar Lagast, Jay A. Barth, on behalf of the ESSENCE Study Group. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin)

**Dedee F. Murrell**, Anne W. Lucky, Julio C. Salas-Alanis, David T. Woodley, Francis Palisson, Ken Natsuga, Milos Nikolic, Mae Ramirez-Quizon, Amy S. Paller, Irene Lara-Corrales, Mohammadreza Amir Barzegar, Eli Sprecher, Cristina Has, Martin Laimer, Anna L. Bruckner, Asli Bilgic, Arti Nanda, Diana Purvis, Alain Hovnanian, Slobodna Murat-Sušić, Johannes Bauer, Johannes S. Kern, Christine Bodemer, Linda K. Martin, Jemima Mellerio, Cezary Kowaleski, Susan J. Robertson, Leena Bruckner-Tuderman, Elena Pope, M Peter Marinkovich, Jean Y. Tang, John Su, Jouni Uitto, Lawrence F. Eichenfield, Joyce Teng, Mark Jean Aan Koh, Sang Eun Lee, Phuong Khuu, Heather I. Rishel, Mette Sommerlund, Karen Wiss, Chao-Kai Hsu, Tor Wo Chiu, Anna E. Martinez: Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic – Consensus: Recommendations by an International Panel of Experts J Am Acad Dermatol. 2020 Jul 16 doi: 10.1016/j.jaad.2020.06.1023

Amir Teimourpour, Kowsar Hedayat, Fereshteh Salarvand, Narges Ghandi, Maryam Ghiasi, Hamidreza Mahmoudi, Kamran Balighi, Roja Toosi, Farnam Mohebi, Ali Nili, Maryam Daneshpazhooh, **Dedee F. Murre**ll, Cheyda Chams-Davatchi. Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris . Int J Womens Dermatol. 2020 Sep; 6(4): 306–310. Published online 2020 Mar 26. doi: 10.1016/j.ijwd.2020.03.043

Goodale EC, White SD, Bizikova P, Borjesson D, **Murrell DF**, Bisconte  A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, Jordan TJM, Emery CB, Outerbridge CA. Open trial of Bruton&#39;s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. Vet Dermatol 2020;31:410-e110. <https://doi.org/10.1111/vde.12878>

Daniel BS, **Murrell DF**: The role of women as past and present advocates for vaccination: relevance in the COVID-19 setting. Int J Womens Derm 2020 https://doi.org/10.1016/j.ijwd.2020.10.001

Paller AS, Browning J, Nikolic M, Bodemer C, **Murrell DF**, Lenon W, Krusinska E, Reha A, Lagast H, Barth JA; ESSENCE Study Group. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet J Rare Dis. 2020 Jun 23;15(1):158. doi: 10.1186/s13023-020-01419- 3.PMID: 32576219

**Murrell DF**, Paller AS, Bodemer C, Browning J, Nikolic M, Barth JA, Lagast H, Krusinska E, Reha A; ESSENCE Study Group. Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. Orphanet J Rare Dis. 2020 Jul 21;15(1):190. doi: 10.1186/s13023-020-01435-3.PMID: 32693833

Gorell ES, Wolstencroft PW, de Souza MP, **Murrell DF,** Linos E, Tang JY. Financial burden of epidermolysis bullosa on patients in the United States. Pediatr Dermatol. 2020 Nov;37(6):1198-1201. doi: 10.1111/pde.14340. Epub 2020 Sep 8.

Goldust M, Sharma A, **Murrell DF,** Kazemi N, Rudnicka L, Kassir M, Navarini A, Mueller SM. Dermatology and specialty rotations: COVID-19 may reemphasize the importance of internal medicine. Dermatol Ther. 2020 Nov;33(6):e13996. doi: 10.1111/dth.13996. Epub 2020 Aug 11.PMID: 32652827

Kang M, Chen JSC, Radjenovic M, Yang A, Feng GHY, **Murrell DF**. An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study. Exp Dermatol. 2020 Dec 21. doi: 10.1111/exd.14252. Online ahead of print.PMID: 33347654

Shakshouk H, Daneshpazhooh M, **Murrell DF**, Lehman JS. Authors&#39; reply to the comment & quot; Treatment considerations for patients with pemphigus during the COVID-19 pandemic & quot;. J Am Acad Dermatol. 2021 Jan;84(1):e61-e62. doi: 10.1016/j.jaad.2020.09.002. Epub 2020 Sep 4.PMID: 32896598

Kasperkiewicz M, Schmidt E, Amagai M, Fairley JA, Joly P, **Murrell DF**, Payne AS, Yale ML, Zillikens D, Woodley DT. Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021 Mar 2. doi: 10.1111/jdv.17207. Online ahead of print.PMID: 33655539

**Murrell DF**, Joly P, Werth VW. Guidelines for the use of prophylactic agents in pemphigus patients treated with rituximab depend on the individual patient’s risk factors. J Am Acad Derm 2021 (in press March)

Teimourpour A, Hedayat K, Salarvand F, Ghandi G, Ghiasi M, Mahmoudi H, Balighi K, Toosi R, Mohebi F, Nili A, Daneshpazhooh M, **Murrell DF**, Chams-Davatchi C. Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris . Int J Womens Dermatol. 2020 Sep; 6(4): 306–310. Published online 2020 Mar 26. doi: 10.1016/j.ijwd.2020.03.043

Clare L Rogers, Matthew Gibson, Johannes S.Kern Linda K Martin, Susan J.Robertson, i , Oliver G.C.Murrell, GrantFeng, **Dedee F Murrell.** A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB) JAAD International  2(12):134-152 DOI: 10.1016/j.jdin.2020.12.007

**Dedee F. Murrell**, Aikaterini Patsatsi, Panagiotis Stavropoulos,Sharon Baum, Tal Zeeli, Johannes S. Kern, Angeliki-Viktoria Roussaki-Schulze, Rodney Sinclair, Ioannis Bassukas, Dolca Thomas, Ann Neale, Frédéric Caux, Victoria P. Werth, MD, Steven G. Gourlay, and Pascal Joly, MD 13 Proof-of-concept for immune-mediated clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor, for patients with pemphigus vulgaris in the phase 2 BELIEVE study. Br J Dermatol online 03 May 2021 <https://doi.org/10.1111/bjd.20431>

Genevieve Ho,  Tabrez Sheriff ,  M. Doria-Ruiz ,  Y. Loh ,  **Dedee F. Murrell** Are biosimilars for pemphigus safe? Clin Exp Dermatol 46(5): 942-943, 2021 [https://doi.org/10.1111/ced.14610 345](https://doi.org/10.1111/ced.14610%20345).

 Aikaterini Patsatsi, **Dedee F. Murrell**. Bruton tyrosine kinase inhibition and its role as an emerging treatment in pemphigus. Front Med (Lausanne) 2021; 8: 708071. Published online 2021 Aug 10. doi: 10.3389/fmed.2021.708071

Bishnoi A Manjunath S, Kishore K, De D, Handa S, **Murrell DF**, Mahajan R. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa: and its correlation with the clinical severity assessment scores: a cross-sectional study. IADVL: 2021. DOI 10.25259/IJDVL\_31\_20.

Montagnon, C.M., Tolkachjov, S.N., **Murrell, D.F.,** Camilleri, M.J. &amp; Lehman, J.S. Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. J Am Acad Dermatol 84, 1507-1519 (2021).

Montagnon, C.M., Tolkachjov, S.N., **Murrell, D.F.,** Camilleri, M.J. &amp; Lehman, J.S. Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. J Am Acad Dermatol 85, 1-14 (2021).

Montagnon, C.M., Lehman, J.S., **Murrell, D.F**., Camilleri, M.J. &amp; Tolkachjov, S.N. Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. J Am Acad Dermatol 84, 1523-1537 (2021).

Montagnon, C.M., Lehman, J.S., **Murrell, D.F.,** Camilleri, M.J. &amp; Tolkachjov, S.N. Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. J Am Acad Dermatol 85, 18-27 (2021).

Zeng FY, **Murrell DF**: State of the Art Review: Autoimmune blisteirng diseases in humans. Veterinary Derm 2021.

H. Rashid ,  A. Lamberts ,  L. Borradori ,  S. Alberti-Violetti ,  R.J. Barry ,  M. Caproni ,  B. Carey,  M. Carrozzo ,  F. Caux ,  G. Cianchini ,  A. Corrà ,  G.F.H. Diercks ,  F.G. Dikkers ,  G.Di Zenzo,  C. Feliciani ,  G. Geerling ,  G. Genovese ,  M. Hertl ,  P. Joly ,  A.V. Marzano ,  J.M. Meijer ,  V. Mercadante **,  D.F. Murrell** ,  M. Ormond ,  H.H. Pas ,  A. Patsatsi ,  C. Prost ,  S. Rauz ,  B.D. van Rhijn ,  M. Roth ,  E. Schmidt ,  J. Setterfield ,  G. Zambruno ,  D. Zillikens B.Horváth . European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. JEADV 10 th July online 2021 https://doi.org/10.1111/jdv.17397

E. Schmidt , H. Rashid , A.V. Marzano , A. Lamberts , G. Di Zenzo , G.F.H. Diercks , S. Alberti- Violetti , R.J. Barry , L. Borradori , M. Caproni , B. Carey , M. Carrozzo , G. Cianchini , A. Corrà , F.G. Dikkers , C. Feliciani , G. Geerling , G. Genovese , M. Hertl , P. Joly , J.M. Meijer , V. Mercadante , **D.F. Murrell** , M. Ormond , H.H. Pas , A. Patsatsi , S. Rauz , B.D. van Rhijn , M. Roth , J. Setterfield , D. Zillikens ,  C.Prost , G. Zambruno , B. Horváth , F. Caux . European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II JEADV <https://doi.org/10.1111/jdv.17395>

Aikaterini Patsatsi, **Dedee F. Murrell**. Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus .Front Med (Lausanne) 2021; 8: 708071. Published online 2021 Aug 10. doi: 10.3389/fmed.2021.708071 D.F. Murrell, A. Patsatsi, P. Stavropoulos, S. Baum, T. Zeeli, J.S. Kern, A.‐V. Roussaki‐Schulze, R. Sinclair, I.D. Bassukas, D. Thomas, A. Neale, P. Arora, F. Caux, V.P. Werth, S.G. Gourlay, P. Joly, the BELIEVE trial investigators Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study Br J Dermatol. 2021 Oct; 185(4):745–755. doi: 10.1111/bjd.20431

Yicong Liang, Faith A.P. Zeng, Tabrez Sheriff, Anna Wilson, Asli Bilgic, Grant Feng, John H. Stone, **Dedee F. Murrell** Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: A cohort study JAAD Int. 2022 Mar; 6: 68–76. Published online 2022 Jan 12. doi: 10.1016/j.jdin.2021.09.003

Anna Wilson and **Dedee F. Murrell**: Clinical features of chronic bullous diseases of childhood. Clin Exp Dermatol Jan 2022 online. doi:10.1111/ced.15059